Streetbeat News

Stock Prices

BLMN

Over the past three months, 7 analysts have shared their evaluations of Bloomin Brands (NASDAQ:BLMN), revealing a range of outlooks from bullish to bearish. The average 12-month price target has decreased by 20.77% to $20.71. Analysts from firms like Citigroup, Deutsche Bank, and Barclays have lowered their ratings and price targets for BLMN, reflecting concerns about the company's recent performance and financial metrics.

Portfolio Pulse from Benzinga Insights

August 19, 2024 | 12:00 pm

LQDA

Liquidia shares are trading lower after the FDA granted tentative approval for YUTREPIA inhalation powder to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 11:55 am

ZIM

ZIM Integrated Shipping Services shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 guidance.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 11:52 am

SPRC

SciSparc Ltd. (NASDAQ: SPRC) has signed an exclusive patent license agreement with Polyrizon Ltd to out-license its SCI-160 program for pain treatment. SciSparc will receive Polyrizon securities valued at $3 million and potentially milestone fees and royalties. SCI-160 has shown promising preclinical results. Additionally, SciSparc has agreed to a merger with AutoMax Motors Ltd. SPRC stock is up 21.8% in premarket trading.

Portfolio Pulse from Vandana Singh

August 19, 2024 | 11:51 am

LAB

PAPL

PMN

The article highlights notable insider transactions for three penny stocks: Pineapple Financial Inc. (NYSE:PAPL), ProMIS Neurosciences, Inc. (NASDAQ:PMN), and Standard BioTools Inc. (NASDAQ:LAB). Insider purchases can indicate confidence in the company's prospects. Pineapple Financial's CEO bought 2,000 shares despite a wider-than-expected quarterly loss. ProMIS Neurosciences' Director acquired 10,000 shares following a second-quarter GAAP loss. Standard BioTools' Director purchased 1,200,000 shares after reporting worse-than-expected financial results and cutting FY24 revenue guidance.

Portfolio Pulse from Avi Kapoor

August 19, 2024 | 11:48 am

GOOGL

META

NVDA

SPY

TSM

VOO

Nvidia Corp (NASDAQ:NVDA) has seen significant changes in hedge fund ownership, with Citadel and DE Shaw reducing their stakes, while Renaissance Technologies and Marshall Wace increased their investments. Nvidia's stock has gained close to 3% in the last 30 days. SoftBank Group Corp has shifted to Taiwan Semiconductor Manufacturing Co (NYSE:TSM) for AI chip production, and is exploring partnerships with Alphabet Inc (NASDAQ:GOOGL) (NASDAQ:GOOG) and Meta Platforms Inc (NASDAQ:META). Investors can gain exposure to Nvidia through Vanguard S&P 500 ETF (NYSE:VOO) and SPDR S&P 500 (NYSE:SPY).

Portfolio Pulse from Anusuya Lahiri

August 19, 2024 | 11:48 am

AMZN

COST

CVS

WBA

WMT

Retail pharmacy chains like CVS Health and Walgreens Boots Alliance are facing significant challenges due to shifting consumer habits, operational inefficiencies, and financial pressures. Declining prescription drug reimbursement rates, competition from e-commerce giants like Amazon, and inflation are eroding profit margins. CVS is dealing with losses in its insurance business and has announced cost cuts, while Walgreens is struggling with its primary care push. Both companies are seeing reduced sales as consumers turn to cheaper alternatives like Walmart and Costco.

Portfolio Pulse from Vandana Singh

August 19, 2024 | 11:43 am

PROP

Prairie Operating Co. (NASDAQ:PROP) has secured $24 million from Watermill Capital Partners through the exercise of Series E B Warrants, simplifying its capital structure and enhancing its position for long-term growth.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 11:37 am

MIRA

MIRA Pharmaceuticals Inc. (NASDAQ:MIRA) is nearing the submission of its Investigational New Drug (IND) application for Ketamir-2 by the end of the year. The company has strengthened its leadership with the appointment of Dr. Itzchak Angel as Chief Scientific Advisor. Significant progress has been made with Ketamir-2, a novel oral ketamine analog, which has shown a superior safety profile and efficacy in preclinical studies. Additionally, MIRA-55, a novel oral pharmaceutical marijuana analog, has demonstrated promising results and is not classified as a controlled substance by the DEA.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 11:35 am

PLTR

VTI

Palantir Technologies Inc (NYSE:PLTR) CEO Alex Karp defended the company's military and government partnerships, emphasizing a pro-Western stance. Despite facing criticism, Karp remains unapologetic about supporting U.S. government operations and AI development. Palantir reported strong Q2 revenue growth, with commercial and government revenues up 33% and 23% year-over-year, respectively. Analysts and investors, including Wedbush Securities and Ark Invest, have shown strong support for the stock. PLTR has surged over 121% in the last 12 months. Investors can also gain exposure through Vanguard Mid-Cap ETF (NYSE:VO) and Vanguard Total Stock Market ETF (NYSE:VTI).

Portfolio Pulse from Anusuya Lahiri

August 19, 2024 | 11:30 am